AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 JAN 24 - (NewsRx.com & NewsRx.net) -- Ariad Pharmaceuticals, Inc., reported January 8, 2001, the results of in vivo studies demonstrating promising new applications of its Argent(TM) regulated cell-elimination technology for both the treatment and prevention of prostate cancer.
These findings, based on studies in animals with implanted human prostate tumors, were presented at the Keystone Symposium, "Gene Therapy 2001: A Gene Odyssey," by Ariad collaborator David Spencer, PhD, from Baylor College of Medicine, Houston, Texas.
In the first set of in vivo studies, scientists delivered the gene for the Argent cell-death switch directly to the implanted prostate tumor using an adenovirus and then administered Ariad's gene-activating dimerizer drug to the animals. The tumor cells took up the cell-death gene, and the drug successfully caused controlled death and elimination of the prostate cancer cells.
The killed tumor cells then were used to develop a prostate cancer vaccine. Administration of this Argent cell-based vaccine to animals with implanted prostate tumors led to a significant delay in tumor growth, whereas use of cells killed by several alternative methods had little or no effect. Furthermore, in ...
Source: HighBeam Research, Cell-Elimination Technology Has Therapy and Vaccine Potential.(Brief...